Analyst Consensus ?
ConsensusHold28 ratings
Bullish828.6%
Neutral1657.1%
Bearish414.3%
GSK plc · GSK · FY2026 Q1 · Calendar Q2 2026
GSK’s Q1 growth was led by specialty medicines and Shingrix
GSK’s Q1 showed a growth profile led by specialty medicines and vaccines, with early launch traction and a broad late-stage pipeline supporting management’s maintained full-year guidance. The key test is whether Exdensur, Nucala COPD, Blenrep and long-acting HIV products can convert pipeline and launch momentum into sustained growth while regulatory, pricing and competitive risks remain manageable.
Reported Before market openNYSEHealthcare
$99.24B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.24
Consensus $1.16
EPS surprise
+6.9%
Reported versus consensus
Reported revenue
$10.30B
Consensus $10.23B
Revenue surprise
+0.7%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-5.6%
Event window
SPY move
-0.0%
Same window
Abnormal move
-5.6%
Stock minus SPY
Volume
2.8×
Versus trailing sessions
Subsequent drift
-0.3%
Up to 20 sessions
GSKSPY benchmark
Ask FN2 about GSK FY2026 Q1
Transcript, numbers and history already loaded
Why did GSK fall 5.6% after beating EPS estimates in FY2026 Q1?What changed in GSK's guidance and outlook in FY2026 Q1?Give me the bull and bear case for GSK after FY2026 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the current quarter added evidence of execution: specialty medicines grew 14%, Shingrix delivered a record quarter, and management highlighted early traction for Nucala in COPD, Exdensur and Blenrep. The company also cited breakthrough designation and priority review progress for bepirovirsen, expected Exdensur J-code timing, and a 34,000-patient Shingrix dementia trial.
Guidance delta
Full-year guidance was maintained; no increase or reduction was supplied in the current analysis.
Key takeaways
- Specialty medicines and vaccines were the primary growth engines, with Shingrix reaching record quarterly sales.
- Management highlighted early launch traction in Nucala COPD, Exdensur and Blenrep.
- The long-acting HIV pipeline and multiple Phase III readouts remain important future milestones.
- Acquisitions and business development are broadening the respiratory and cardiopulmonary portfolio.
Management priorities
- Execute specialty-medicine and vaccine launches, including Nucala COPD, Exdensur and Blenrep.
- Advance bepirovirsen, Jemperli, camlipixant and other late-stage pipeline programs.
- Continue long-acting HIV development and the Shingrix dementia outcome trial.
Follow GSK with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$49.51Current
$35.25Low
$48.86Average
$60High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 1, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Jefferies | Hold | Buy | Downgrade | Oct 29, 2026 |
| Barclays | Underweight | Equal Weight | Downgrade | Jan 6, 2026 |
| Guggenheim | Neutral | Buy | Downgrade | Oct 31, 2024 |
| UBS | Neutral | Buy | Downgrade | Jul 8, 2024 |
| DZ Bank | Hold | Buy | Downgrade | Feb 11, 2022 |
| SVB Leerink | Market Perform | Outperform | Downgrade | Mar 23, 2021 |
| Deutsche Bank | Sell | Hold | Downgrade | Feb 4, 2021 |
| Argus Research | Buy | Buy | Maintain | Nov 11, 2019 |
| New Street | Hold | Reduce | Upgrade | Oct 16, 2019 |
| Cantor Fitzgerald | Buy | Hold | Upgrade | Oct 11, 2019 |
| Societe Generale | Buy | Sell | Upgrade | Sep 3, 2019 |
| Exane BNP Paribas | Neutral | Outperform | Downgrade | Jan 14, 2019 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | Dec 14, 2018 |
| Morgan Stanley | Underweight | Underweight | Maintain | Dec 14, 2018 |
| Argus | Buy | Buy | Maintain | Aug 20, 2018 |
| Bank of America | Neutral | Buy | Downgrade | Oct 26, 2017 |
| Citigroup | Neutral | Buy | Downgrade | Jul 5, 2017 |
| PiperJaffray | Overweight | Overweight | Maintain | Sep 23, 2016 |
| Bryan Garnier | Buy | Neutral | Upgrade | Jan 27, 2016 |
| Credit Suisse | Neutral | Underperform | Upgrade | Oct 20, 2015 |
| JP Morgan | Neutral | Underweight | Upgrade | Oct 12, 2015 |
| Mainfirst | Underperform | Underperform | Maintain | Jul 28, 2014 |
| Panmure | Buy | Hold | Upgrade | Apr 22, 2014 |
| S&P Capital IQ | Hold | Sell | Upgrade | Jan 27, 2014 |
| Berenberg | Hold | Buy | Downgrade | Jan 24, 2014 |
| Cowen & Co. | Market Perform | Outperform | Downgrade | Jan 22, 2014 |
| Liberum | Hold | Underweight | Upgrade | Jun 7, 2013 |
| Kepler Cheuvreux | Buy | Hold | Upgrade | Feb 8, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $49.51. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Jefferies | Analyst unavailable | $55.9 | $48.74 | +12.9% | Oct 29, 2026 |
| Berenberg Bank | Kerry Holford | $60 | $50.05 | +21.2% | Sep 15, 2026 |
| CFRA | Wan Nurhayati | $53 | $46.67 | +7.0% | Oct 30, 2025 |
| BNP Paribas | Peter Verdult | $35.25 | $35.68 | -28.8% | Apr 15, 2025 |
| Jefferies | Peter Welford | $53 | $38.38 | +7.0% | Jul 2, 2024 |
| Guggenheim | Vamil Divan | $36 | $40.69 | -27.3% | Apr 11, 2024 |
Track every rating change on GSK the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationGSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio.…
Historical context
All GSK earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| AZN AstraZeneca PLC | FY2026 Q3 · Calendar Q4 2026 | +7.3% | +7.0% | AstraZeneca pairs solid growth with pipeline investment and restructuring |
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +10.0% | BrightSpring posts strong Q3 growth as pharmacy leads |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.6% | +13.3% | Regeneron posts strong Q3 growth as pipeline expands |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the GSK recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-01T04:50:43.409939+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-01T04:50:43.406938+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-01. For educational purposes only; not investment advice.